[Etripamil for atrioventricular-node-dependent supraventricular tachycardia]
- PMID: 38010401
- DOI: 10.1007/s00108-023-01623-w
[Etripamil for atrioventricular-node-dependent supraventricular tachycardia]
References
Literatur
-
- Brugada J, Katritsis DG, Arbelo E et al (2020) 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4258. Eur Heart J 41(5):655–720. https://doi.org/10.1093/eurheartj/ehz467 - DOI - PubMed
-
- Hamer A, Peter T, Platt M, Mandel WJ (1981) Effects of verapamil on supraventricular tachycardia in patients with overt and concealed Wolff-Parkinson-White syndrome. Am Heart J 101(5):600–612. https://doi.org/10.1016/0002-8703(81)90227-1 - DOI - PubMed
-
- Stambler BS, Plat F, Sager PT et al (2022) First randomized, multicenter, placebo-controlled study of self-administered Intranasal etripamil for acute conversion of spontaneous paroxysmal Supraventricular tachycardia (NODE-301). Circ Arrhythm Electrophysiol 15(12):e10915. https://doi.org/10.1161/CIRCEP.122.010915 - DOI - PubMed - PMC
-
- Ip JE, Coutu B, Bennett MT, Pandey AS, Stambler BS, Sager P, Chen M, Shardonofsky S, Plat F, Camm AJ (2023) Etripamil nasal spray for conversion of repeated spontaneous episodes of paroxysmal supraventricular tachycardia during long-term follow-up: results from the NODE-302 study. J Am Heart Assoc 12:e28227. https://doi.org/10.1161/JAHA.122.028227 - DOI - PubMed - PMC